checkAd
    Startseite > Aktien > Phathom Pharmaceuticals > Nachrichten
    Phathom Pharmaceuticals Aktie
    9,1800
     
    USD
    +0,88 %
    +0,0800 USD
    Letzter Kurs 22:30:00 Nasdaq
    9,1800
     
    USD
    4.200 STK
    Geldkurs 22:02:00
    9,1900
     
    USD
    300 STK
    Briefkurs 22:02:00
    ISIN: US71722W1071 · WKN: A2PT0F · SYM: PHAT · USA

    Neueste Nachrichten

    Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    03.04.24 · globenewswire · Phathom Pharmaceuticals
    Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
    26.03.24 · globenewswire · Phathom Pharmaceuticals
    Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    07.03.24 · globenewswire · Phathom Pharmaceuticals
    Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
    29.02.24 · globenewswire · Phathom Pharmaceuticals
    Phathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
    13.02.24 · globenewswire · Phathom Pharmaceuticals
    Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    31.01.24 · globenewswire · Phathom Pharmaceuticals
    Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
    28.11.23 · globenewswire · Phathom Pharmaceuticals
    Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
    09.11.23 · globenewswire · Phathom Pharmaceuticals
    Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
    01.11.23 · globenewswire · Phathom Pharmaceuticals
    Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA TRIPLE PAK (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA DUAL PAK (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
    30.10.23 · globenewswire · Phathom Pharmaceuticals
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    25.10.23 · globenewswire · Phathom Pharmaceuticals
    Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
    26.09.23 · globenewswire · Phathom Pharmaceuticals